A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: Novel insights into the diverse biological effects of perlecan

EuroIntervention

Volumn 6, Issue 1, 2010, Pages 134-140

  Segev, Amit ^a,b   Nili, Nafiseh ^a   Osherov, Azriel B ^a   Qiang, Beiping ^a   Wong, Amy J ^a   Pillarisetti, Sivaram ^c   Strauss, Bradley H ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b TEL AVIV UNIVERSITY   (Israel)

^c Reddy US Therapeutics   (United States)

Author keywords

Drug delivery; Drug eluting stent; Pharmacology

Indexed keywords

ENZYME INHIBITOR; FOCAL ADHESION KINASE; GELATINASE B; PERLECAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RUS 3108; THYMIDINE; UNCLASSIFIED DRUG; CARDIOVASCULAR AGENT; GELATINASE A; PROTEOHEPARAN SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA; ARTICLE; BARE METAL STENT; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; EXPERIMENTAL RABBIT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IN-STENT RESTENOSIS; MORPHOMETRICS; MUSCLE FUNCTION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SMOOTH MUSCLE FIBER; ANIMAL; CATTLE; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; HYPERPLASIA; INSTRUMENTATION; INTIMA; METABOLISM; PATHOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RABBIT; TIME; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON; ANIMALS; CARDIOVASCULAR AGENTS; CATTLE; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; HEPARAN SULFATE PROTEOGLYCANS; HYPERPLASIA; ILIAC ARTERY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RABBITS; TIME FACTORS; TUNICA INTIMA; UP-REGULATION;

EID: 77957270361     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV6I1A20     Document Type: Article

References (30)

1. Iozzo RV, Cohen IR, Grässel S, Murdoch AD. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J. 1994;302:625-639. (Pubitemid 24289294)
2. Segev A, Nili N, Strauss NH. The role of perlecan in arterial injury and angiogenesis. Cardiovasc Res. 2004;63:603-10. (Pubitemid 39078673)
3. Brown JC, Sasaki T, Gohring W, Yamada Y, Timpl R. The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem. 1997;250:39-46. (Pubitemid 27504580)
4. Noonan DM, Fulle A, Valente P, Cai S, Horigan E, Sasaki M, Yamada Y, Hassell JR. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem. 1991;266:22939-22947. (Pubitemid 21908742)
5. Whitelock JM, Graham LD, Melrose J, Murdoch AD, Iozzo RV, Underwood PA. Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol. 1999;18:163-178. (Pubitemid 29229702)
6. Hopf M, Gohring W, Kohfeldt E, Yamada Y, Timpl R. Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin. Eur J Biochem. 1999;259:917-925. (Pubitemid 29075524)
7. Hayashi K, Madri JA, Yurchenco PD. Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan. J Cell Biol. 1992;119:945-959.
8. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest. 1998;102:1599-1608. (Pubitemid 28492228)
9. Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell. 1994;79:1005-1013.
10. Kunjathoor VK, Chiu DS, O'Brien KD, LeBoeuf RC. Accumulation of Biglycan and Perlecan, but Not Versican, in Lesions of Murine Models of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:462-468. (Pubitemid 34218755)
11. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest. 1998;102:1599-1608. (Pubitemid 28492228)
12. Forsten KE, Courant NA, Nugent MA. Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J Cell Physiol. 1997;172:209-220. (Pubitemid 27339083)
13. Paka L, Goldberg IJ, Obunike JC, Choi SY, Saxena U, Goldberg ID, Pillarisetti S. Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells: an underlying mechanism for the modulation of smooth muscle growth? J Biol Chem. 1999;274:36403-36408.
14. Lundmark K, Tran PK, Kinsella MG, Clowes AW, Wight TN, Hedin U. Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate. J Cell Physiol. 2001;188:67-74. (Pubitemid 32476497)
15. Koyama N, Kinsella MG, Wight TN, Hedin U, Clowes AW. Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells. Circ Res. 1998;83:305-313. (Pubitemid 28371320)
16. Nugent MA, Nugent HM, Iozzo RV, Sanchack K, Edelman ER. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA. 2000;97:6722-6727. (Pubitemid 30412781)
17. Segev A, Aviezer D, Safran M, Gross Z, Yayon A. Inhibition of vascular smooth muscle cell proliferation by a novel fibroblast growth factor receptor antagonist. Cardiovasc Res. 2002;53:232-241. (Pubitemid 34020785)
18. Strauss BH, Robinson R, Batchelor WB, Chisholm RJ, Ravi G, Natarajan MK, Logan RA, Mehta SR, Levy DE, Ezrin AM, Keeley FW. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res. 1996;79:541-550.
19. Walker HA, Whitelock JM, Garl PJ, Nemenoff RA, Stenmark KR, Weiser-Evans MC. Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol Biol Cell. 2003;14:1941-52. (Pubitemid 36583544)
20. Whitelock JM, Graham LD, Melrose J, Murdoch AD, Iozzo RV, Underwood PA. Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol. 1999;18:163-178. (Pubitemid 29229702)
21. Knox S, Merry C, Stringer S, Melrose J, Whitelock J. Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. J Biol Chem. 2002;277:14657-14665. (Pubitemid 34952534)
22. Delmolino LM, Stearns NA, Castellot JJ Jr. COP-1, a member of the CCN family, is a heparin-induced growth arrest specific gene in vascular muscle cells. J Cell Physiol. 2001;188:45-55. (Pubitemid 32476495)
23. Berry D, Shriver Z, Natke B, Kwan CP, Venkataraman G, Sasisekharan R. Heparan sulphate glycosaminoglycans derived from endothelial cells and smooth muscle cells differentially modulate fibroblast growth factor-2 biological activity through fibroblast growth factor receptor-1. Biochem J. 2003;373:241-249. (Pubitemid 36819518)
24. Lundmark K, Tran PK, Kinsella MG, Clowes AW, Wight TN, Hedin U. Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate. J Cell Physiol 2001;188:67-74. (Pubitemid 32476497)
25. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy titters in the angiogenesis area. J Clin Invest. 2001;108:349-355. (Pubitemid 32730778)
26. Kinsella MG, Tran PK, Weiser-Evans MC, Reidy M, Majack RA, Wight TN. Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler Thromb Vasc Biol. 2003;23:608-14. (Pubitemid 36438073)
27. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL. Twentyeight- day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 2002;13:183-188. (Pubitemid 34747967)
28. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188-1193. (Pubitemid 32830406)
29. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001;104:473-479. (Pubitemid 32678280)
30. Raman VK, Edelman ER. Coated stents: local pharmacology. Semin Interv Cardiol. 1998;3:133-7.